In search of a new paradigm for protective immunity to TB

Nature Reviews Microbiology

Volumn 12, Issue 4, 2014, Pages 289-299

  Nunes Alves, Cláudio ^a,b,c   Booty, Matthew G ^a,d   Carpenter, Stephen M ^a,e   Jayaraman, Pushpa ^a   Rothchild, Alissa C ^a,d   Behar, Samuel M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD1 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12;

ADAPTIVE IMMUNITY; APOPTOSIS; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL LOAD; BACTERIAL TRANSMISSION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYSOSOME; MACROPHAGE; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOSOME; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84896388520     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3230     Document Type: Review

References (166)

1. Russell, D. G., Barry, C. E. 3rd & Flynn, J. L. Tuberculosis: what we don't know can, and does, hurt us. Science 328, 852-856 (2010).
2. Cooper, A. M., Mayer-Barber, K. D. & Sher, A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4, 252-260 (2011).
3. Chackerian, A. A., Alt, J. M., Perera, T. V., Dascher, C. C. & Behar, S. M. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun. 70, 4501-4509 (2002). (Pubitemid 34790962)
4. Wolf, A. J. et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205, 105-115 (2008). (Pubitemid 351185719)
5. Reiley, W. W. et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl Acad. Sci. USA 105, 10961-10966 (2008).
6. Flynn, J. L., Chan, J. & Lin, P. L. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 4, 271-278 (2011).
7. Horsburgh, C. R. Jr. & Rubin, E. J. Clinical practice. Latent tuberculosis infection in the United States. New Engl. J. Med. 364, 1441-1448 (2011).
8. Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845-855 (2009).
9. Fine, P. E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345 (1995).
10. North, R. J. Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell. Immunol. 7, 166-176 (1973).
11. Orme, I. M., Roberts, A. D., Griffin, J. P. & Abrams, J. S. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 151, 518-525 (1993). (Pubitemid 23207017)
12. Shimokata, K., Kishimoto, H., Takagi, E. & Tsunekawa, H. Determination of the T-cell subset producing gamma-interferon in tuberculous pleural effusion. Microbiol. Immunol. 30, 353-361 (1986). (Pubitemid 16122961)
13. Mogues, T., Goodrich, M. E., Ryan, L., LaCourse, R. & North, R. J. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193, 271-280 (2001). (Pubitemid 32524511)
14. Behar, S. M., Dascher, C. C., Grusby, M. J., Wang, C. R. & Brenner, M. B. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189, 1973-1980 (1999). (Pubitemid 29295896)
15. Geldmacher, C., Zumla, A. & Hoelscher, M. Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr. Opin. HIV AIDS 7, 268-275 (2012).
16. Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254 (1993). (Pubitemid 23344886)
17. Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993). (Pubitemid 23344885)
18. Chan, J., Xing, Y., Magliozzo, R. S. & Bloom, B. R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175, 1111-1122 (1992).
19. MacMicking, J. D., Taylor, G. A. & McKinney, J. D. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 302, 654-659 (2003). (Pubitemid 37310923)
20. Gutierrez, M. G. et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753-766 (2004). (Pubitemid 40017683)
21. MacMicking, J. D. et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94, 5243-5248 (1997). (Pubitemid 27214768)
22. Fabri, M. et al. Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci. Transl. Med. 3, 104ra102 (2011).
23. Liu, P. T., Stenger, S., Tang, D. H. & Modlin, R. L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179, 2060-2063 (2007).
24. Casanova, J. L. & Abel, L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581-620 (2002). (Pubitemid 34293435)
25. Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186, 39-45 (1997). (Pubitemid 27304845)
26. Sonnenberg, P. et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191, 150-158 (2005). (Pubitemid 40096371)
27. Murray, J. et al. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS 21, S97-S104 (2007). (Pubitemid 350158894)
28. + T helper cell depletion occurs. J. Clin. Invest. 82, 1908-1914 (1988). (Pubitemid 19054937)
29. Geldmacher, C. & Koup, R. A. Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection. Trends Immunol. 33, 207-214 (2012).
30. Alcais, A., Fieschi, C., Abel, L. & Casanova, J. L. Tuberculosis in children and adults: two distinct genetic diseases. J. Exp. Med. 202, 1617-1621 (2005). (Pubitemid 41815866)
31. Wallis, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect. Dis. 13, 362-372 (2013).
32. Diel, R., Loddenkemper, R., Niemann, S., Meywald-Walter, K. & Nienhaus, A. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 183, 88-95 (2011).
33. Mattila, J. T., Diedrich, C. R., Lin, P. L., Phuah, J. & Flynn, J. L. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J. Immunol. 186, 3527-3537 (2011).
34. Lazarevic, V., Nolt, D. & Flynn, J. L. Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J. Immunol. 175, 1107-1117 (2005). (Pubitemid 41094997)
35. Abebe, F., Mustafa, T., Nerland, A. H. & Bjune, G. A. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin. Exp. Immunol. 143, 180-192 (2006).
36. Mittrücker, H.-W. et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl Acad. Sci. USA 104, 12434-12439 (2007). (Pubitemid 47206155)
37. Mollenkopf, H.-J., Hahnke, K. & Kaufmann, S. H. E. Transcriptional responses in mouse lungs induced by vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Microbes Infect. 8, 136-144 (2006). (Pubitemid 43139301)
38. Oliveira, E. S., Marinho, J. M. & Barbosa, T. Interferon-gamma production by mononuclear cells in Bacille Calmette-Guérin-re vaccinated healthy volunteers predicted long-term antimycobacterial responses in a randomized controlled trial. Vaccine 31, 3778-3782 (2013).
39. Soares, A. P. et al. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 180, 3569-3577 (2008).
40. + T cell response. J. Immunol. 177, 5647-5651 (2006). (Pubitemid 44527640)
41. Andersen, A. et al. The immunological effect of revaccination with Bacille Calmette-Guérin vaccine at 19 months of age. Vaccine 31, 2137-2144 (2013).
42. Kagina, B. M. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073-1079 (2010).
43. + T cells mediate IFN-y-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J. Immunol. 171, 4689-4699 (2003). (Pubitemid 37310586)
44. Gallegos, A. M. et al. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog. 7, e1002052 (2011).
45. Miller, H. E. & Robinson, R. T. Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages. Infect. Immun. 80, 3828-3841 (2012).
46. Nandi, B. & Behar, S. M. Regulation of neutrophils by interferon-y limits lung inflammation during tuberculosis infection. J. Exp. Med. 208, 2251-2262 (2011).
47. Jayaraman, P. et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J. Exp. Med. 207, 2343-2354 (2010).
48. Green, A. M., Difazio, R. & Flynn, J. L. IFN-y from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J. Immunol. 190, 270-277 (2013).
49. H17, and innate lymphoid IFN-y and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J. Immunol. 189, 4079-4087 (2012).
50. Flynn, J. L. et al. Tumor necrosis factor-a is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995).
51. Mayer-Barber, K. D. et al. Caspase-1 independent IL-1 p production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J. Immunol. 184, 3326-3330 (2010).
52. Gonzalez-Juarrero, M. et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J. Leukoc. Biol. 77, 914-922 (2005). (Pubitemid 40770843)
53. Ladel, C. H. et al. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 65, 4843-4849 (1997). (Pubitemid 27463266)
54. Chan, J., Tanaka, K., Carroll, D., Flynn, J. & Bloom, B. R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63, 736-740 (1995).
55. Jung, J. Y. et al. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. Infect. Immun. 81, 3198-3209 (2013).
56. Weinberg, J. B. et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86, 1184-1195 (1995).
57. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl Acad. Sci. USA 97, 8841-8848 (2000). (Pubitemid 30626635)
58. Aston, C, Rom, W. N., Talbot, A. T. & Reibman, J. Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am. J. Respiratory Crit. Care Med. 157, 1943-1950 (1998).
59. Saunders, B. M., Briscoe, H. & Britton, W. J. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 137, 279-287 (2004). (Pubitemid 39013073)
60. Mohan, V. P. et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69, 1847-1855 (2001). (Pubitemid 32187645)
61. Tobin, D. M. et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717-730 (2010).
62. Bean, A. G. et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162, 3504-3511 (1999). (Pubitemid 29313602)
63. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
64. Denis, M. & Ghadirian, E. Granulocyte-macrophage colony-stimulating factor restricts growth of tubercle bacilli in human macrophages. Immunol. Lett. 24, 203-206 (1990). (Pubitemid 20162400)
65. Bermudez, L. E. & Young, L. S. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J. Leukoc. Biol. 48, 67-73 (1990). (Pubitemid 20206345)
66. Rothchild, A. C, Jayaraman, P., Nunes-Alves, C. & Behar, S. M. iNKT cell production of GM-CSF controls Mycobacterium tuberculosis. PLoS Pathog. 10, e1003805 (2014).
67. Trapnell, B. C. & Whitsett, J. A. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev Physiol. 64, 775-802 (2002). (Pubitemid 34259249)
68. Rosen, L. B. et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190, 3959-3966 (2013).
69. Jayaraman, P. et al. IL-1 p promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J. Immunol. 190, 4196-4204 (2013).
70. + T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog. 8, e1002984 (2012).
71. Sada-Ovalle, I. et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J. Immunol. 189, 5896-5902 (2012).
72. Desvignes, L. & Ernst, J. D. Interferon-y-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 31, 974-985 (2009).
73. Cruz, A. et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 207, 1609-1616 (2010).
74. Novikov, A. et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1 p production in human macrophages. J. Immunol. 187, 2540-2547 (2011).
75. Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
76. Martineau, A. R. et al. IFN-y-and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol. 178, 7190-7198 (2007). (Pubitemid 46847445)
77. Verway, M. et al. Vitamin D induces interleukin-1 p expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog. 9, e1003407 (2013).
78. Yuk, J. M. et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6, 231-243 (2009).
79. Ralph, A. P., Lucas, R. M. & Norval, M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect. Dis. 13, 77-88 (2013).
80. Vilcheze, C, Hartman, T., Weinrick, B. & Jacobs, W. R. Jr. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nature Commun. 4, 1881 (2013).
81. Chen, C. Y et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5, e1000392 (2009).
82. Skinner, M. A., Parlane, N., McCarthy, A. & Buddle, B. M. Cytotoxic T-cell responses to Mycobacterium bovis during experimental infection of cattle with bovine tuberculosis. Immunology 110, 234-241 (2003). (Pubitemid 37249263)
83. + T cells and their role in immunity. Crit. Rev. Immunol. 26, 317-352 (2006). (Pubitemid 44423550)
84. + T cells require perforin to kill target cells and provide protection in vivo. J. Immunol. 181, 8595-8603 (2008).
85. Turner, J. et al. CD8-and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am. J. Respir. Cell. Mol. Biol. 24, 203-209 (2001). (Pubitemid 32152083)
86. Sousa, A. O. et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc. Natl Acad. Sci. USA 97, 4204-4208 (2000). (Pubitemid 30226111)
87. Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125 (1998). (Pubitemid 28471143)
88. Behar, S. M., Divangahi, M. & Remold, H. G. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nature Rev. Microbiol. 8, 668-674 (2010).
89. Martin, C. J. et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 12, 289-300 (2012).
90. Saunders, B. M. et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 174, 4852-4859 (2005).
91. Botha, T. & Ryffel, B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol. 171, 3110-3118 (2003). (Pubitemid 37093534)
92. Saunders, B. M., Frank, A. A., Orme, I. M. & Cooper, A. M. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell. Immunol. 216, 65-72 (2002). (Pubitemid 35193446)
93. -/- mice is dependent on T cells and IL-12. J. Immunol. 165, 483-492 (2000). (Pubitemid 30429542)
94. Lawn, S. D., Butera, S. T. & Shinnick, T. M. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect. 4, 635-646 (2002). (Pubitemid 34614552)
95. Ly, L. H., Russell, M. I. & McMurray, D. N. Cytokine profiles in primary and secondary pulmonary granulomas of Guinea pigs with tuberculosis. Am. J. Respir. Cell. Mol. Biol. 38, 455-462 (2008). (Pubitemid 351758692)
96. Manabe, Y. C. et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.) 88, 187-196 (2008).
97. Via, L. E. et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infection Immun. 81, 2909-2919 (2013).
98. Lin, P. L. Sterilization of granulomas is common in both active and latent tuberculosis despite extensive within-host variability in bacterial killing. Nature Med. 20, 75-79 (2013).
99. Kwan, C. K. & Ernst, J. D. HIV and tuberculosis: a deadly human syndemic. Clin. Microbiol. Rev. 24, 351-376 (2011).
100. Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
101. Guyot-Revol, V., Innes, J. A., Hackforth, S., Hinks, T. & Lalvani, A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 173, 803-810 (2006).
102. + T cells in regulation of the immune response during human tuberculosis. Clin. Exp. Immunol. 144, 25-34 (2006).
103. Green, A. M. et al. CD4 regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J. Infect. Dis. 202, 533-541 (2010).
104. Scott-Browne, J. P. et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204, 2159-2169 (2007). (Pubitemid 47360876)
105. Kursar, M. et al. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 178, 2661-2665 (2007). (Pubitemid 46333142)
106. Shafiani, S., Tucker-Heard, G., Kariyone, A., Takatsu, K. & Urdahl, K. B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J. Exp. Med. 207, 1409-1420 (2010).
107. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006). (Pubitemid 43237609)
108. Lazar-Molnar, E. et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc. Natl Acad. Sci. USA 107, 13402-13407 (2010).
109. Jurado, J. O. et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 181, 116-125 (2008).
110. Barber, D. L, Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H. & Sher, A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J. Immunol. 186, 1598-1607 (2011).
111. Pedrosa, J. et al. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect. Immun. 68, 577-583 (2000). (Pubitemid 30056510)
112. Rivas-Santiago, B. et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect. Immun. 76, 935-941 (2008). (Pubitemid 351428052)
113. Yang, C. T. et al. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 12, 301-312 (2012).
114. + T cells during Mycobacterium tuberculosis infection. J. Immunol. 186, 7110-7119 (2011).
115. Cruz, A. et al. Cutting edge: IFN-y regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J. Immunol. 177, 1416-1420 (2006). (Pubitemid 44092473)
116. Mishra, B. B. et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1 (3. Nature Immunol. 14, 52-60 (2013).
117. Berry, M. P. R. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010).
118. Naranbhai, V. et al. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J. Infect. Dis. 209, 500-509 (2013).
119. Maglione, P. J. & Chan, J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 39, 676-686 (2009).
120. Huang, D. et al. Immune distribution and localization of phosphoantigen-specific Vy2V52 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infect. Immun. 76, 426-436 (2008).
121. Millet, J. P. et al. Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse? PLoS ONE 8, e64898 (2013).
122. Millet, J. P. et al. Tuberculosis recurrence and its associated risk factors among successfully treated patients. J. Epidemiol. Commun. Health 63, 799-804 (2009).
123. Crofts, J. P., Andrews, N. J., Barker, R. D., Delpech, V. & Abubakar, I. Risk factors for recurrent tuberculosis in England and Wales, 1998-2005. Thorax 65, 310-314 (2010).
124. Dobler, C. C, Crawford, A. B., Jelfs, P. J., Gilbert, G. L & Marks, G. B. Recurrence of tuberculosis in a low-incidence setting. Eur. Respir. J. 33, 160-167 (2009).
125. van Rie, A. et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174-1179 (1999).
126. Kamath, A. B., Alt, J., Debbabi, H. & Behar, S. M. Toll like receptor 4-defective C3H/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis. Infection Immun. 71, 4112-4118 (2003). (Pubitemid 36753740)
127. Kamath, A. B., Alt, J., Debbabi, H., Taylor, C. & Behar, S. M. The major histocompatibility complex haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect. Immun. 72, 6790-6798 (2004). (Pubitemid 39552346)
128. Pan, H. et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434, 767-772 (2005). (Pubitemid 44739520)
129. Johnson, S. Antibody responses to clostridial infection in humans. Clin. Infect. Dis. 25, S173-177 (1997).
130. Chackerian, A., Alt, J., Perera, V. & Behar, S. M. Activation of NKT cells protects mice from tuberculosis. Infection Immun. 70, 6302-6309 (2002). (Pubitemid 35192722)
131. Sun, R. et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27, 4412-4423 (2009).
132. Rao, M. et al. The tuberculosis vaccine candidate Bacillus Calmette-Guérin AureC:hly coexpressing human interleukin-7 or-18 enhances antigen-specific T cell responses in mice. PLoS ONE 8, e78966 (2013).
133. Desel, C. et al. Recombinant BCG AureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J. Infecti. Diseases 204, 1573-1584 (2011).
134. Peixoto, A. et al. CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. J. Exp. Med. 204, 1193-1205 (2007). (Pubitemid 46798161)
135. Jameson, S. C. & Masopust, D. Diversity in T cell memory: an embarrassment of riches. Immunity 31, 859-871 (2009).
136. Ottenhoff, T. H. M. & Kaufmann, S. H. E. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8, e1002607 (2012).
137. Brennan, M. J., Stone, M. R. & Evans, T. A rational vaccine pipeline for tuberculosis. Int. J. Tuberculosis Lung Dis.16, 1566-1573 (2012).
138. Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013).
139. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240-1244 (2004). (Pubitemid 39540442)
140. + T cells. Eur. J. Immunol. 40, 279-290 (2010).
141. Vavassori, S. et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human yd T cells. Nature Immunol. 14, 908-916 (2013).
142. D'Souza, C. D. et al. A novel nonclassic (32-microglobulin-restricted mechanism influencing early lymphocyte accumulation and subsequent resistance to tuberculosis in the lung. Am. J. Respir Cell. Mol. Biol. 23, 188-193 (2000). (Pubitemid 30656428)
143. Sugawara, I. et al. Mycobacterial infection in natural killer T cell knockout mice. Tuberculosis (Edinb.) 82, 97-104 (2002). (Pubitemid 35155425)
144. Khader, S. A. et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-y responses if IL-12p70 is available. J. Immunol. 175, 788-795 (2005). (Pubitemid 41094960)
145. Montoya, C. J. et al. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin. Immunol. 127, 1-6 (2008).
146. Sutherland, J. S. et al. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis (Edinb.) 89, 398-404 (2009).
147. Im, J. S. et al. Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin. Immunol. 127, 214-224 (2008). (Pubitemid 351474599)
148. Van Rhijn, I. et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nature Immunol. 14, 706-713 (2013).
149. Kasmar, A. G. et al. CD1b tetramers bind a(3 T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J. Exp. Med. 208, 1741-1747 (2011).
150. Ly, D. et al. CD1c tetramers detect ex vivo T cell responses to processed phosphomycoketide antigens. J. Exp. Med. 210, 729-741 (2013).
151. Gold, M. C. et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. 8, e1000407 (2010).
152. Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nature Immunol. 11, 701-708 (2010).
153. Havlir, D. V, Ellner, J. J., Chervenak, K. A. & Boom, W. H. Selective expansion of human yS T cells by monocytes infected with live Mycobacterium tuberculosis. J. Clin. Invest. 87, 729-733 (1991).
154. + T cell subsets contribute to the human anti-mycobacterial immune response. J. Immunol. 180, 1962-1970 (2008).
155. Sada-Ovalle, I., Chiba, A., Gonzales, A., Brenner, M. B. & Behar, S. M. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-y, and kill intracellular bacteria. PLoS Pathog. 4, e1000239 (2008).
156. Gold, M. C. et al. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. Mucosal Immunol. 6, 35-44 (2013).
157. Lockhart, E., Green, A. M. & Flynn, J. L. IL-17 production is dominated by yS T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol. 177, 4662-4669 (2006). (Pubitemid 44469799)
158. Sada-Ovalle, I., Sköld, M., Tian, T, Besra, G. S. & Behar, S. M. a-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am. J. Respiratory Crit. Care Med. 182, 841-847 (2010).
159. Chen, C. Y. et al. Phosphoantigen/IL2 expansion and differentiation of Vy2V52 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog. 9, e1003501 (2013).
160. Gansert, J. L. et al. Human NKT cells express granulysin and exhibit antimycobacterial activity. J. Immunol. 170, 3154-3161 (2003). (Pubitemid 36302192)
161. Venkataswamy, M. M. et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 183, 1644-1656 (2009).
162. + T cells during mycobacterial infections. Science 295, 2255-2258 (2002). (Pubitemid 34258837)
163. Umemura, M. et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 178, 3786-3796 (2007). (Pubitemid 46417647)
164. Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 184, 4414-4422 (2010).
165. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunol. 8, 369-377 (2007). (Pubitemid 46745412)
166. H1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol. 42, 364-373 (2012).